Literature DB >> 18592004

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Marieta I Toma1, Marianne Grosser, Alexander Herr, Daniela E Aust, Axel Meye, Christian Hoefling, Susanne Fuessel, Daniela Wuttig, Manfred P Wirth, Gustavo B Baretton.   

Abstract

Genetic aberrations are crucial in renal tumor progression. In this study, we describe loss of heterozygosity (LOH) and DNA-copy number abnormalities in clear cell renal cell carcinoma (cc-RCC) discovered by genome-wide single nucleotide polymorphism (SNP) arrays. Genomic DNA from tumor and normal tissue of 22 human cc-RCCs was analyzed on the Affymetrix GeneChip Human Mapping 10K Array. The array data were validated by quantitative polymerase chain reaction and immunohistochemistry. Reduced DNA copy numbers were detected on chromosomal arm 3p in 91%, on chromosome 9 in 32%, and on chromosomal arm 14q in 36% of the tumors. Gains were detected on chromosomal arm 5q in 45% and on chromosome 7 in 32% of the tumors. Copy number abnormalities were found not only in FHIT and VHL loci, known to be involved in renal carcinogenesis, but also in regions containing putative new tumor suppressor genes or oncogenes. In addition, microdeletions were detected on chromosomes 1 and 6 in genes with unknown impact on renal carcinogenesis. In validation experiments, abnormal protein expression of FOXP1 (on 3p) was found in 90% of tumors (concordance with SNP array data in 85%). As assessed by quantitative polymerase chain reaction, PARK2 and PACRG were down-regulated in 57% and 100%, respectively, and CSF1R was up-regulated in 69% of the cc-RCC cases (concordance with SNP array data in 57%, 33%, and 38%). Genome-wide SNP array analysis not only confirmed previously described large chromosomal aberrations but also detected novel microdeletions in genes potentially involved in tumor genesis of cc-RCC.

Entities:  

Mesh:

Year:  2008        PMID: 18592004      PMCID: PMC2435001          DOI: 10.1593/neo.08160

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  35 in total

1.  Association between early-onset Parkinson's disease and mutations in the parkin gene.

Authors:  C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

2.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression.

Authors:  Alexandra Giatromanolaki; Michael I Koukourakis; Efthimios Sivridis; Kevin C Gatter; Adrian L Harris; Alison H Banham
Journal:  Mod Pathol       Date:  2006-01       Impact factor: 7.842

4.  Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas.

Authors:  Iwona Kardas; Krzysztof Mrózek; Malgorzata Babinska; Kazimierz Krajka; Piotr Hadaczek; Jan Lubinski; Andrzej Roszkiewicz; Ewa Kuziemska; Janusz Limon
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

5.  Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.

Authors:  Xabier Agirre; José Román-Gómez; Iria Vázquez; Antonio Jiménez-Velasco; Leire Garate; Cristina Montiel-Duarte; Paula Artieda; Lucia Cordeu; Idoya Lahortiga; María José Calasanz; Anabel Heiniger; Antonio Torres; John D Minna; Felipe Prósper
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

6.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays.

Authors:  K Lindblad-Toh; D M Tanenbaum; M J Daly; E Winchester; W O Lui; A Villapakkam; S E Stanton; C Larsson; T J Hudson; B E Johnson; E S Lander; M Meyerson
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

7.  Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.

Authors:  A Martinez; P Fullwood; K Kondo; T Kishida; M Yao; E R Maher; F Latif
Journal:  Mol Pathol       Date:  2000-06

Review 8.  Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer.

Authors:  Hai-Tao Zheng; Zhi-Hai Peng; Sheng Li; Lin He
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

9.  Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene.

Authors:  J Zhao; A Yart; S Frigerio; A Perren; P Schraml; C Weisstanner; T Stallmach; W Krek; H Moch
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

10.  Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma.

Authors:  Kazuhiro Nagao; Shiro Yamaguchi; Hideyasu Matsuyama; Yoshihito Korenaga; Hiroshi Hirata; Satoru Yoshihiro; Koji Fukunaga; Kazuo Oba; Katsusuke Naito
Journal:  Cancer Genet Cytogenet       Date:  2005-07-01
View more
  41 in total

1.  Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.

Authors:  Toru Inoue; Keiko Matsuura; Taichiro Yoshimoto; Lam Tung Nguyen; Yoshiyuki Tsukamoto; Chisato Nakada; Naoki Hijiya; Takahiro Narimatsu; Takeo Nomura; Fuminori Sato; Yoji Nagashima; Kenji Kashima; Shingo Hatakeyama; Chikara Ohyama; Kazuyuki Numakura; Tomonori Habuchi; Masayuki Nakagawa; Masao Seto; Hiromitsu Mimata; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2012-01-20       Impact factor: 6.716

Review 2.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth.

Authors:  Julia Menke; Jörg Kriegsmann; Carl Christoph Schimanski; Melvin M Schwartz; Andreas Schwarting; Vicki R Kelley
Journal:  Cancer Res       Date:  2011-11-03       Impact factor: 12.701

4.  Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.

Authors:  Zhenhua Hu; Liancheng Zhu; Jian Gao; Mingbo Cai; Mingzi Tan; Juanjuan Liu; Bei Lin
Journal:  Tumour Biol       Date:  2015-04-21

5.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

6.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

Review 8.  An emerging role of PARK2 in cancer.

Authors:  Liang Xu; De-chen Lin; Dong Yin; H Phillip Koeffler
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

9.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

10.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.